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plete cytogenetic and molecular. Prognosis was assigned to each category,
according to disease progression and mortality. Prognosis was also assigned to
BMT patients. Unit costs were drawn from national databases, and multiplied by
resource use (driven by response level and disease status) to estimate total costs.
Health benefits weremeasured using quality-adjusted life years (QALYs), based on
the patient’s current health status and level of response. Univariate and probabi-
listic sensitivity analyses were conducted to estimate the confidence around the
results. RESULTS: Dasatinib resulted in 6.425 QALYs, at a total cost of £314,413, per
patient. QALYs and costs for comparators were as follows: imatinib 400mg, 1.485,
£135,326; imatinib 600mg, 2.394, £173,705; imatininb 800mg, 5.910, £350,365; nilo-
tinib, 6.235, £228,576; interferon-a, 1.664, £6,764; BMT, 4.738, £302, 937. Incremental
cost-effectiveness ratios (ICER) for dasatinib against competitors were as follows:
imatinib 400mg, £36,251; imatinib 600mg, £34,907; imatinib 800mg, dominant; ni-
lotinib, dominant; interferon-a, £38,877; BMT, dominant. CONCLUSIONS:Dasatinib
was more effective than imatinib 400mg, 600mg 800mg, nilotinib, interferon-a and
BMT in the treatment of chronic-phase imatinib-resistant patients CML. The analysis
estimates dasatinib treatment to be less costly than imatinib 800mg, nilotinib and
BMT, dominating these treatments in the cost-effectiveness analysis. Dasatinib is
therefore a cost-effective treatment option for patients in the CP of CML.
PCN69
AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF
IMATINIB RESISTANT PATIENTS WITH ADVANCED PHASE CHRONIC
MYELOGENOUS LEUKAEMIA
Taylor M1, Lewis L1, Lebmeier M2, Wang Q2
1York Health Economics Consortium, York, North Yorkshire, UK, 2Bristol-Myers Squibb,
Uxbridge, Middlesex, UK
OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease asso-
ciated with significant health and economic burden. This study estimates the life-
time costs and health outcomes associated with dasatinib in the treatment of
imatinib-resistant CML patients who have the accelerated or blast stages of the
disease.METHODS: AMarkovmodel was developed to estimate lifetime outcomes
based on initial best response, which was defined as: no response, complete
haematologic, partial cytogenetic, complete cytogenetic, molecular. Prognosis was
assigned to each category, according to disease progression and mortality. Unit
costs were drawn from national databases, and multiplied by resource use (driven
by response level and disease status) to estimate total costs. Health benefits were
measured using quality-adjusted life years (QALYs), based on patients’ health sta-
tus and response. Univariate and probabilistic sensitivity analyses were conducted
to estimate confidence around the results. RESULTS: In AP, dasatinib resulted in
2.603 QALYs, at a cost of £170,478 per patient. QALYs and costs for comparators
were: imatinib 600mg, 0.583, £88,949; imatininb 800mg, 0.583, £96,552; nilotinib,
1.697, £141,128; BMT, 2.861, £230,277. Incremental cost-effectiveness ratios (ICER)
for dasatinib against competitors were: imatinib 600mg, £40,357; imatinib 800mg,
£36,594; nilotinib, £32,405, BMT, £231,650. In BP, dasatinib resulted in 0.485 QALYs,
at a total cost of £105,103, per patient. QALYs and costs for comparators were:
imatinib 600mg, 0.240, £108,306; imatinib 800mg, 0.240, £115,123; BMT, 1.757,
£173,892. ICERs for dasatinib against competitors were: imatinib 600mg, dominant;
imatinib 800mg, dominant; BMT, £54,093. CONCLUSIONS: In imatinib-resistant AP
CML, dasatinib was more effective than imatinib 600mg, 800mg and nilotinib, and
less costly than BMT. In BP CML, dasatinib wasmore effective than imatinib 600mg
and 800mg and less costly than imatinib 600mg, 800mg, nilotinib and BMT. Dasat-
inib is, therefore, cost-effectiveness when compared against other pharmacologi-
cal interventions in the treatment of advanced stages of CML.
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OBJECTIVES: Decision analysis (DA) is commonly used to perform economic eval-
uations of new pharmaceuticals. However, DA analyses can also be used to deter-
mine a drug price that would be considered cost effective based on recommended
thresholds for economic value. Usingmultiples of Malaysia’s per capita GDP as the
threshold for economic value as suggested by the World Health Organization
(WHO), DA was used to estimate a price per dose for bevacizumab in Malaysia, a
drug that provides a 1.4 month survival benefit to patients with metastatic colo-
rectal cancer (mCRC).METHODS: A DA model was developed to simulate progres-
sion free and overall survival in mCRC patients receiving chemotherapy with and
without bevacizumab. Outcomes for cancer control and side effects were obtained
from randomized trials evaluating 1st and 2nd line chemotherapy in mCRC. Costs
for chemotherapy and side effects management were obtained from both public
and private hospitals in Malaysia. Utility estimates measured as quality adjusted
life years (QALYs) were determined by interviewing 24 oncology nurses using the
Time Trade-Off technique. The price per dose was then estimated using a target
threshold of $44,400 per QALY gained, which is three times the Malaysian per
capita GDP. RESULTS: A cost effective price for bevacizumab could not be reached
because of the short survival benefit provided. If the drug were able to improve
survival from 1.4 to 3 or 6 months, then the price per dose could be $U.S.567 and
$U.S.1,258 and be considered cost effective in Malaysia according to the WHO
criteria. CONCLUSIONS: The use of DA modeling for estimating drug price is a
powerful technique to ensure value formoney. Such information can be of value to
both drug manufacturers and formulary committees because it would facilitate
negotiations for value-based pricing in a given jurisdiction.
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OBJECTIVES:One of themajor barriers to cancer drug access has been price, which is
oftenbeyond themeansofnationalhealth carebudgets in lessdevelopedcountries. In
this study,wepresent anovel approach to estimate a value basedprice for newcancer
drugs that considers thewealthof anation.Todemonstrate this approach, pharmaco-
economic (PE) modeling was used to estimate a value based South African price for
bevacizumab, a drug that provides a 1.4 month survival benefit to patients with met-
astatic colorectal cancer (mCRC). The threshold used for economic value was 3 times
the South African per capita gross domestic product (GDP), as recommended by the
WorldHealthOrganization (WHO).METHODS:APEmodelwas developed to simulate
theoutcomes inmCRCpatients receiving chemotherapybevacizumab.Clinical data
were obtained from randomized trials and costs from a South African cancer center.
Utility estimateswere determined by interviewing 16 oncology nurses involved in the
care of mCRC patients. A price per dose of bevacizumab was then estimated using a
target threshold of $U.S.32,000 per quality adjusted life year (QALY) gained, which is 3
times the South African per capita GDP. RESULTS: A cost effective price for bevaci-
zumabcouldnot be reachedbecause of the short survival benefit. If thedrugwere able
to improve survival from 1.4 to 3 or 6 months, then the price per dose could be
$U.S.58.00 and $U.S.258.00 and be considered cost effective in South Africa according
to the WHO criteria. CONCLUSIONS: A value based pricing approach using PE mod-
eling and the WHO criteria for economic value is feasible for South Africa. This ap-
proachwould be a good starting point for opening dialogue betweenmedical schemes
and the pharmaceutical industry to identify an optimal drug price that would be ac-
ceptable to all of the key stakeholders.
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OBJECTIVES:Adjuvant chemotherapy decisions for womenwith early-stage breast
cancer are complex. Oncotype DX, a gene expression profiling test, is validated at
predicting distant recurrence-free response in patients with ER LN- early-stage
breast cancer. This enables chemotherapy to be better targeted at higher risk pa-
tients than is possible through the use of Adjuvant! Online (AOL) or clinical judge-
ment alone. However, existing cost-effectiveness analyses of Oncotype DX have
numerous limitations: in particular, they consider a limited range of strategies and
do not separately consider intermediate risk patients identified through either AOL
or Oncotype DX. Our objective was to build an Ontario-based cost-effectiveness
analysis which comprehensively addresses these limitations.METHODS:We built
upon a Markov model developed by Tsoi and colleagues, using data from the
NSABP B-14 and B-20 clinical trials.We assumed that AOL andOncotypeDXmay be
provided separately or sequentially and considered the chemotherapy decision
separately for every possible risk group, resulting in 1000 unique strategies for the
provision of AOL, Oncotype DX and chemotherapy. RESULTS: Oncotype DX ap-
pears cost-effective for all patients, regardless of a patient’s initial AOL risk assess-
ment. The highest ICER is in patients at low AOL risk ($29,000 per QALY), while
Oncotype DX dominates in patients at high AOL risk. Chemotherapy appears cost-
effective only in patients at intermediate or high Oncotype DX risk. The highest
ICER is in patients at low AOL and intermediate Oncotype DX risk ($64,000 per
QALY). Chemotherapy is dominated in patients at low Oncotype DX risk.
CONCLUSIONS: Oncotype DX appears to be cost-effective for all Ontario women
with ER LN- early-stage breast cancer, regardless of the woman’s initial AOL risk
assessment. These results have informed the Ontario Health Technology Advisory
Committee’s recent deliberations regarding the funding of OncotypeDX inOntario.
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OBJECTIVES: The main objective of this study was to evaluate the utilisation of
antineoplastic drugs during the period of 2004-2009 in Slovak Republic.METHODS:
Data involving the number of medicine packages, DDD and financial expenditures
abstracted from the Slovak Institute for Drug control were analysed to evaluate the
antineoplastic agents consumption. RESULTS: The obtained data showed slight
increase in antineoplastic agents consumption from 2004 (21,03 DID (DDD/1000
inhabitants/ day) to 2007 (30,94 DID). Between 2007 and 2009 slight decrase in DID
(from 30,94 in 2007 to 27,10 in 2009) was observed. Antimetabolits raised DID con-
sumption between 2004 (9,88) and 2007 (14,13) and declined in 2009 (10,12 ). The
consumption of alkylating agents in terms ofDIDwas varying from4,4 in 2004 to 8,3
in 2007 and 7,38 in 2009, cytotoxic antibiotics and related substances reached 0,41
in 2004, 0,74 in 2007 and 0,73 in 2009, plant alkaloids and other natural products
quoted 2,04 in 2004 and 2,67 in 2009. Total expenditures for antineoplastic drugs
multiplied from 21 736 185 € (2004) to 105 589 161 € (2009). Highest consumption in
terms of financial units was reached in 2004 by: docetaxel (2 328 233€ ), paclitaxel
( 2 259 313€ ) and gemcitabine (2 062 914€ ); in 2009 by: bevacizumab (17 049 381 €),
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trastuzumab (11 703 935 €), rituximab (9 153 856 €); in terms of DID: ifosfamid (3,43
(2004) and 6,3 (2009)), gemcitabine (4,88 (2004) and 4,66 (2009)), fluorouracil (3,14
(2004) and 2,85 (2009)). CONCLUSIONS: Financial expenditures for antineoplastic
agents are rising due to use of newand expensivemedications,which are supposed
to double within coming years and are expected to decrease one third of cancer
mortality. Senescent population with higner incidence of cancer disease is ex-
pected to slightly increase DID and medicine packages consumption.
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OBJECTIVES: Breast cancer forms in tissues of thebreast, usually inducts and lobules.
It is themost common type ofwoman‘s cancer in Slovakia (age- standardized rate- 48,
incidence rate - 2016 new cases every year, mortality rate 773 deaths annually ). The
aim of this study was to provide comparable and reliable data of utilisation of stage I
(invasive, up to 2 centimeters, no lymph nodes involved) and stage II (invasive, 2-5
centimeters, lymph nodes might be involved, over 5 centimeters- no lymph nodes
involvement) breast cancer drugs within the period 2004-2009.METHODS: Analysed
datawere abstracted fromSlovak Institute forDrugControl,which collects them from
wholesalers. Data were studied in accordance with Daily Defined Dose (DDD, with
exception of trastuzumab) and in financial units (€). RESULTS: The consumption of
drugs used in stage I and II breast cancer had increasing trend in terms of financial
burdens between 2004 and 2009 with anastrozole ( from 1 378 317 € to 1 888 478 €),,
doxorubicine (from776 400 € to 1 354 072 €),methotrexate ( from138 954 € to 650 993 €)
and trastuzumab (from 359 797 € to 11 703 935 €) decreasing trend with tamoxifen (
from261417 € to 159064 €) nadalternating trendwith cyclofosfamide ( 206156 € (2004),
223 867 € (2006), 207 042 € (2009)), epirubicine ( 238 125 € (2004), 908 690 € (2007), 629 757
€ (2009)) and fluorouracil ( 444 627 € (2004), 455 578 € (2006), 339 232 € (2009)). Highest
consumption in terms of DDD showed fluorouracil (3,24 DID (DDD/1000 inhabitants/
day) in 2006, 2007, 2008) andhighest increase ofDDDanastrazole ( 0,14DID (2004), 0,46
DID (2009)). CONCLUSIONS: Optimal treatment of breast cancer requires different
therapies. Trastuzumab is well established on Slovak market due to good reasults in
early stage treatment with few recidives. Consumption of tamoxifen and anastrozole
will be influenced by exemestane.
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OBJECTIVES: Within the framework of Chronic Myelogenous Leukaemia (CML)
treatment in Peru, and based on a previously performed economic evaluation, we
compared the costs and cost-effectiveness ratio of using 100mg/day and 140 mg/
day doses of Dasatinibwith the use of 800mg/day doses of Nilotinib or an increased
dose of Imatinib (800mg/day), for each phase of the disease, in patients who devel-
oped resistance to habitual doses of Imatinib. METHODS: A Markov model was
used for this economic evaluation, which considered a cohort of 10.000 CML pa-
tients in its three phases (chronic, accelerated and blast phase), a lifetime horizon
and a 3.5 % discount rate for costs and benefits. Model results included the costs of
each treatment alternative with Dasatinib, Nilotinib or Imatinib, and Quality Ad-
justed Life Years (QALYs) gained. Costs were measured in Peruvian SOLES of year
2010. RESULTS: In the chronic phase of the disease, dasatinib 100 mg/day yielded
the highest amount of QALYs with 6,62 and the lowest cost-effectiveness ratio. In
the accelerated phase, Dasatinib 140mg/day also showed the lowest cost-effective-
ness compared to Nilotinib and Imatinib. In the blast phase, dasatinib showed
lower cost-effectiveness ratio than imatinib.CONCLUSIONS:Dasatinib 100mg/day
showed the lowest cost-effectiveness ratios than doses of 800 mg/day of Nilotinib
and imatinib 800 mg for the treatment of patients with CML resistant to usual
imatinib doses in the chronic phase, as well as in the accelerated and blast phases.
Although there was an overall cost increase, especially due to the cost of Dasatinib
in 140 mg/day doses, this fact was explained by the increase in life years gained
and, consequently, the use of medical resources and drugs.
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OBJECTIVES: To determine the burden of bone metastases and health resource
utilisation (HRU) associated with skeletal-related events (SREs) in patients with
advanced cancer. METHODS: This observational study assessed HRU associated
with SREs (defined as spinal cord compression [SCC], surgery to bone [SB], patho-
logic fracture [PF] or radiation to bone [RB]). Patients with breast, lung or prostate
cancer metastatic to bone or multiple myeloma and life expectancy 6 months
were enrolled in centres in Germany, Italy, Spain, UK, Canada and USA after expe-
riencing a SRE. We report here the European HRU data on hospitalisation, which
were collected retrospectively for the 90 days prior to enrolment and prospectively
for approximately 18-21months. RESULTS: 631 eligible patientswith a total of 1282
SREswere enrolled across 95 European sites: 223 (35.3%) had a primary diagnosis of
breast cancer, 135 (21.4%) lung cancer, 120 (19%) prostate cancer and 153 (24.3%)
multiple myeloma. Across all tumour types, for Germany, Italy, Spain and UK,
respectively, the mean number of hospitalisations per SCC (n  91) was 0.85, 0.69,
0.53 and 1.06 with a mean length of stay (per SRE with  1 hospitalisation) of 25.6,
41.1, 34.3 and 27.7 days. For SB (n  137) mean number of hospitalisations per SRE
was 0.90, 0.76, 0.83 and 0.75 withmean stays of 19.4, 19.8, 8.4 and 10.0 days, respec-
tively. For PF (n 254),mean number of hospitalisations per SREwas 0.42, 0.49, 0.49
and 0.39 with mean stays of 18.7, 22.4, 20.2 and 20.7 days, respectively. Mean
number of hospitalisations per RB (n 692) were 0.19, 0.15, 0.16 and 0.07withmean
stays of 17.9, 16.6, 21.9 and 10.4 days respectively.CONCLUSIONS: Each SRE leads to
considerable hospitalisation, which varies by SRE type and country.
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OBJECTIVES: Use of substances (pan, chaalia, ghutka, niswar) is associated with
serious health risks. In Pakistanmost people use substances from early years of life
which keeps them on risk of short life span. It is important to understand the cost
implication and provide knowledge about the effects of these substances. The aim
of this studywas to estimate the costs of using these substances and to understand
the reasons for using substances. METHODS: This was a cross-sectional study
conducted in two residential colonies in Karachi, Pakistan during 2008 and 2009.
Pre-coded structured questionnaire was administered to collect the data on socio
demographics, costs, reasons for use of substances and use of substances per day.
The data was analyzed on SPSS version 18.0. Possible measures were taken to
ensure the confidentiality of all participants. RESULTS: From 124 randomly se-
lected residents, 107 (86%) agreed to respond. All the selected participants were
between the ages 10–71 years (meansd age 36.216.4). Of the total, about one-
fifth of the users were females. Daily use of substances was significantly higher
among males (p0.001). Further, the use was higher among adolescents than
adults (p0.001) and interestingly less educated consumed less thanhigh educated
(P0.06). Males are spending significantly higher on substances; Rs. 3711.5/day
[Rs.930 or (US$13)/month] compared to females. Overall, 41% of the cost is spent on
cigarettes followed by 27% and 23% on local and branded ghutka respectively. The
main reasons for using substances were peer pressure, easy availability of sub-
stances, stress, liking of taste and to treat toothache. CONCLUSIONS: This study
concluded that use of substances is higher among youngmales and they are spend-
ing a lot on them. To prevent this population, regular awareness campaignsmay be
held at community and school level so that, continuous re-enforcement make
them to quit from using any kind of substances.
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OBJECTIVES:Worldwide, prices for cancer drugs have been under downward pres-
sure where several governments havemandated price cuts of branded products. A
better alternative tomandated price cuts would be the estimation of a launch price
based on drug performance, cost effectiveness and a county’s ability to pay. We
developed a global pricing index for new drugs that encompasses all of these attri-
butes in patients with metastatic colorectal cancer (mCRC). METHODS: A phar-
macoeconomic model was developed to simulate clinical outcomes in mCRC pa-
tients receiving chemotherapy with the addition of a “new drug” that improves
survival by 1.4, 3 and 6 months. Cost and health state utility data were obtained
from cancer centers and oncology nurses (n112) in Canada, Spain, India, South
Africa and Malaysia. A price per dose was estimated for each survival increment
using a target value threshold of three times the per capita GDP for each country, as
recommended by the World Health Organization (WHO). Multivariable analysis
was then used to develop the pricing index, which considers survival benefit, per
capita GDP and income dispersion as measured by the Gini coefficient as predictor
variables. RESULTS: Higher survival benefits were associated with elevated drug
prices, especially in wealthier countries such as Canada. For Argentina with a per
capita GDP of $15,000 and a Gini coefficient of 51, the pricing index estimated that
for a drugwhich provides a 4month survival benefit inmCRC, the value based price
would be $U.S.630 per dose. In contrast, the same drug in a wealthier country like
Norway could command a price of $U.S.2,775. CONCLUSIONS: The application of
this index to estimate a price based on cost effectiveness would be a good starting
point for opening dialogue between the key stakeholders and a better alternative to
governments’ mandated price cuts.
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